To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung Cancer

Inclusion Criteria

• •1. Locally advanced and/or metastatic NSCLC diagnosed histologically and/or cytologically;
• •2. Age 18 and above; Eastern Cooperative Oncology Group Physical condition: 0\~1; The expected survival time is more than 3 months;
• •3. The previous report confirmed the presence of an EGFR gene exon 19 deletion mutation or exon 21 L858R mutation, and the investigator verified that the report reflects the patient's current genetic status.
• •4. There is at least one measurable lesion other than brain lesion defined by Response Evaluation Criteria In Solid Tumors 1.1 standard;
• •5. The main organs are functioning well,Adequate laboratory indicators.
• •6. Women of childbearing age should agree to use contraceptives during the study period and for a period of six months after the study; Negative serum or urine pregnancy test within 7 days prior to study inclusion, and must be non-lactating; Male patients should agree to use contraception during the study period and for six months after the end of the study period;
• •7. Patients voluntarily participated in this study, signed informed consent, and had good compliance.